Protein discovery could treat obesity, diabetes

Researchers, led by Suresh Alahari, PhD, Fred Brazda Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, have brought the fight against obesity and diabetes to the cellular level with a study outlining the potential of the Nischarin protein.

Published in the Journal of Biological Chemistry, the study found the Nischarin protein was able to change metabolism in mice. Previous research found the protein acted as a tumor suppressor. Researchers further evaluated Nischarin's effects when interacting with the AMPK gene responsible for metabolic stability.

When bound to AMPK, Nischarin inhibits its activity and led to a decrease in the activation of genes in charge of producing glucose. Nischarin also interacted with the gene for regulating glucose uptake, lowering the level of blood glucose levels in mice and improving glucose and insulin tolerance. Genes involved in fat metabolism and the buildup of fat were also affected, giving the mice an increase in energy and appetite suppression. These factors combined led to a decrease in food intake and weight reduction in mice.

"These studies demonstrate the potential of Nischarin as a regulator of metabolic diseases and suggest suppression of Nischarin function may be a valuable approach in the quest to cure such diseases as diabetes and obesity," wrote Alahari.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup